Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: Findings from the ocrelizumab randomised, double-blind phase 3 clinical trials

Authors

Amit Bar-Or, University of Pennsylvania
Anne H Cross, Washington University School of Medicine in St. Louis
et al.

Journal

eBioMedicine

Publication Date

7-1-2023

Volume

93

First Page

104662

Document Type

Open Access Publication

DOI

10.1016/j.ebiom.2023.104662

Rights and Permissions

Bar-Or A, Thanei GA, Harp C, Bernasconi C, Bonati U, Cross AH, Fischer S, Gaetano L, Hauser SL, Hendricks R, Kappos L, Kuhle J, Leppert D, Model F, Sauter A, Koendgen H, Jia X, Herman AE. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine. 2023 Jul;93:104662. doi: 10.1016/j.ebiom.2023.104662. © 2023 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Bar-Or, Amit; Cross, Anne H; and et al., "Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: Findings from the ocrelizumab randomised, double-blind phase 3 clinical trials." eBioMedicine. 93, 104662 (2023).
https://digitalcommons.wustl.edu/oa_4/2521

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.